### Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the inclusion of triamcinolone hexacetonide on the complementary list of the EML and EMLc for use in the treatment of juvenile idiopathic arthritis. Listing is recommended with a square box to indicate triamcinolone acetonide as a therapeutic alternative for national selection in situations where triamcinolone hexacetonide is not available. The Committee noted that the evidence indicates that triamcinolone hexacetonide is superior to triamcinolone acetate in terms of efficacy and duration of response but has been subject to availability and supply shortages worldwide. As was the case in 2021, the Committee considered that the available evidence was still limited, and of sub-optimal quality, but accepted that use of intra-articular glucocorticoid injections with triamcinolone (hexacetonide, and to a lesser extent acetonide) may be associated with improvements in joint inflammation in oligoarticular forms of juvenile idiopathic arthritis and have advantages over long-term systemic corticosteroid use in terms of harms.